We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Valirx Plc | LSE:VAL | London | Ordinary Share | GB00BLH13C52 | ORD 0.1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.05 | 1.52% | 3.35 | 3.30 | 3.40 | 3.35 | 3.30 | 3.30 | 164,059 | 15:18:31 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Medical Laboratories | 0 | -2.37M | -0.0262 | -1.28 | 3.02M |
From Apr 2019 to Apr 2024
TIDMVAL
RNS Number : 0337F
ValiRx PLC
04 March 2020
ValiRx Plc
("ValiRx" or the "Company")
Shareholder Requisition Notice
London, UK, 4 March 2020: ValiRx Plc (AIM: VAL), a clinical stage biotechnology company, announces that it has received a letter from a group of shareholders (the "Letter") who hold in excess of 5% of the issued share capital of the Company, requiring that the Company convene, as soon as reasonably practicable, a general meeting, at which resolutions will be proposed to remove George Morris and Satu Vainikka as directors of the Company.
The Letter is a requisition under section 303 of the Companies Act 2006.
The Company is mindful that, pursuant to section 304 of the Companies Act 2006, the Company must post a notice convening a general meeting within 21 days from the date on which the requisition notice was received, and this general meeting must be held on a date not more than 28 days after the date of the notice to shareholders convening the general meeting.
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.
For more information, please contact:
Hot Features
Premium
ValiRx plc Tel: +44 (0) 20 3008 4416
www.valirx.com
Kevin Alexander, Non-executive Director Tel: +44 (0) 20 3008 4416
Tarquin Edwards, Head of Communications. Tel: +44 (0) 7879 458
364
tarquin.edwards@valirx.com
Cairn Financial Advisers LLP (Nominated Tel: +44 (0) 20 7213 0880
Adviser)
Liam Murray / Jo Turner / Ludovico
Lazzaretti
Allenby Capital Limited (Joint Broker) Tel: +44 (0) 20 3328 5656
Jeremy Porter / Alex Brearley (Corporate
Finance)
Kelly Gardiner (Equity Sales)
ETX Capital Limited (Joint Broker) Tel: +44 (0) 20 7392 1568
Thomas Smith
Novum Securities Limited (Joint Broker) Tel: +44 (0) 20 7399 9400
Colin Rowbury
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
MSCJIMATMTTMBFM
(END) Dow Jones Newswires
March 04, 2020 10:28 ET (15:28 GMT)
1 Year Valirx Chart |
1 Month Valirx Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
